# MHRA

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mhra-organization
Canonical HTML page: https://getbiobrief.com/entity/mhra-organization

## Timeline

- **2026-07**: First Patient Fulfillment Expected — Private providers anticipate delivering the first courses of the oral medication to patients by early July 2026, though the exact date may vary.
- **2026-06-12**: MHRA Approves Oral Wegovy — The UK's Medicines and Healthcare Products Regulatory Agency licenses the daily semaglutide pill for private prescription, setting eligibility criteria based on BMI.
- **2026-06-12**: Private Pharmacies Begin Taking Orders — Boots, Superdrug, Morrisons and other licensed retailers start selling the Wegovy Pill on the same day as approval, with demand pushing waiting lists towards 100,000.
- **2026-03-25**: Black Market Surge — Current reports highlight the critical risk of black market drugs due to the blurring of medicine and cosmetics.
- **2025-11-20**: Regulatory Pivot — Regulators begin targeting social media platforms for 'cosmetic' marketing of prescription drugs.
- **2024-06-10**: Counterfeit Warning — The WHO issues a global alert regarding falsified semaglutide products found in legitimate supply chains.
- **2023-01-15**: Global Shortages Begin — Novo Nordisk and Eli Lilly report significant supply constraints for semaglutide and tirzepatide.

## Recent coverage (2 stories)

### Oral Semaglutide 25mg Shows 16.6% Weight Loss in OASIS-4 Trial
2026-06-15 08:00:39 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Novo Nordisk's oral Wegovy achieved 16.6% mean weight loss at 64 weeks in the Phase III OASIS-4 trial, with 87% of participants losing ≥5% and one-third losing ≥20%. The once-daily pill uses a SNAC absorption enhancer, triggering MHRA approval and a new phase in the GLP-1 obesity drug race.
Full story: https://getbiobrief.com/story/wegovy-pill-oasis-4-clinical-trial-16-6-percent-weight-loss

### The Cosmetic Blurring of GLP-1 Jabs: A Growing Black Market Regulatory Crisis
2026-03-25 15:52:17 · Sentiment: Negative · Impact: 6/10 · Sources: 3

The rapid transition of GLP-1 weight loss medications from clinical treatments to 'lifestyle' products is creating a regulatory vacuum exploited by black market actors. Health authorities warn that the blurring of medicine and cosmetics is driving a surge in counterfeit drugs and unmonitored usage.
Full story: https://getbiobrief.com/story/glp1-cosmetic-blurring-black-market-risk

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.